A multinational research team led by Columbia University and the La Jolla Institute for Immunology has identified a novel viral target that could help combat the global resurgence of measles.
New images of one of the brain’s fastest-acting proteins—the kainate receptor—are providing critical clues that may lead to targeted therapies for epilepsy and other brain disorders.
Columbia University Medical Center (CUMC) is one of 50 institutions selected nationwide from more than 700 applications for a “Provocative Questions” grant from the National Cancer Institute (NCI).